Tecartus® (brexucabtagene autoleucel) – New indication
October 1, 2021 - Gilead announced the FDA approval of Tecartus (brexucabtagene autoleucel), for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Download PDF
